• Twelve patients with rectal cancer were included in the study.
• Patients received a new medicine called dostarlimab every three weeks for six months.
• Dostarmilab is an antibody that attacks cancer cells by exposing them to the immune system, which kills them.

According to a research published recently in The New England Journal of Medicine, all rectal cancer patients who participated in the study saw their cancer cells vanish, a modest clinical trial that has raised hopes among medical specialists.

Twelve patients with rectal cancer were included in the study, which involved them receiving a new medicine called dostarlimab every three weeks for six months.

Dostarmilab is a monoclonal antibody that attacks cancer cells by exposing them to the immune system, which subsequently kills them.

All of the patients’ medical testing revealed that the cancer cells had vanished. To confirm, several tests like MRI scans, PET scans, biopsies, endoscopic examinations, and physical exams, were undertaken.

[embedpost slug=”/ed-sheerans-touching-video-message-for-a-young-cancer-patient-will-warm-your-heart/”]

The senior study author, Luis Diaz Jr., MD, told The New York Times, “I believe this is the first time this has happened in the history of cancer.”

Andrea Cercek, MD, the primary study author, noted, “There were a lot of happy tears.”

Traditional cancer treatments such as multiagent chemotherapy and radiotherapy, according to an editorial published with the paper, are “gruelling and can produce considerable long-term consequences, including neuropathy, infertility, and bowel and sexual dysfunction.”

[embedpost slug=”/i-wish-i-could-do-something-for-cancer-patients-aima-baig/”]